In this article we report on the development, introduction, and maintenance of a policy to promote rational use of thrombolytic drugs by hospital doctors. The work was undertaken within the framework of the voluntarily operated Riverside East drugs guide (formulary) management system (FMS). The Results over a 15 month period show voluntary compliance by prescribers with the recommended policy. One hundred and seventy-four patients (22% cardiac admissions) presented with acute myocardial infarction. Ofthese 43 (25%) received streptokinase, the first-line recommended drug, 7 received alteplase and none received anistreplase. The savings in drug expenditure from using streptokinase rather than alteplase or anistreplase for the 15-month period of investigation were over £27,000. This work represents an example of the effectiveness of the Riverside East FMS model in influencing prescribing behaviour.
Introduction
Thrombolytic therapy is a proven method of reducing mortality after acute myocardial infarction (AMI). At present there seems to be no major difference in mortality reduction between the three currently available thrombolytic agents although results of further trials are awaited. However, there is a very major difference in cost between these three agents.
In June and July 1988, alteplase had been used free of charge for patients who entered a clinical trial study (SHAPE) . During this time considerable local interest in the use of the drug had been generated. The pharmaceutical manufacturers of alteplase (rt-PA, Actilyse) undertook a series of discussions with district pharmacists, general managers and many other staff, to increase awareness of the launch of alteplase and the considerable potential cost implications for each district. They announced that they planned to sell the drug at a cost of approximately £1000 for a single patient's treatment. Understandably, this aroused much concern because the potential for expenditure on alteplase could have instantly risen from zero to approximately £200,000 based on the estimated number of AMI cases that would present Meetings were held in pharmacy, CCU and ITU to inform staff of the policy and make them aware of their obligations for effective patient management. The policy educated doctors how to use the drugs appropriately ( Figure 1 ). Arrangements were made for storage of drugs and a pump for streptokinase infusion in readiness in the relevant departments. Records ofthe use of thrombolytic drugs for patients with AMI were kept in CCU and ITU departments in order to monitor the effectiveness of our policy. The cardiology senior registrar also held a meeting with junior medical staff involved in the admission of patients with AMI to explain the background and operation of the local policy and to provide professional support. A drugs guide bulletin on management of thrombolysis was first produced in 1988 to communicate the policy. Bulletins were distributed to all medical, nursing and pharmacy staff.
Drugs were selected according to proven efficacy, relative toxicity and cost, as agreed by local specialist opinion. In 1988 when alteplase was first licensed, the local policy recommended streptokinase as the first-line drug of choice. Alteplase was available for patients who had received streptokinase within the last 6 months, because of the risk of antigenicity. Following licensing of anistreplase in September 1989 it was felt appropriate to review the policy. Anistreplase, a pro-drug of streptokinase, still retained allergic potential, therefore alteplase remained the treatment of choice where streptokinase was given in the past 6 months. In the revised policy streptokinase was still considered the first-line choice. Anistreplase and alteplase were recommended as second-line drugs. Anistreplase was available for cases where there was a delay in setting up the streptokinase infusion because of its ease of administration, and alteplase was recommended where either streptokinase or anistreplase had been given in the last 6 months. Figure 2 shows part of the 1989 bulletin which briefly compares aspects of the three drugs streptokinase, alteplase and anistreplase that were considered by members of the task force group. The bulletins also provided guidelines for the management of AMI. The policy was reinforced by ward pharmacists.
Results
In the 6-month period, January to June 1988, before the SHAPE study no alteplase had been given to patients presenting with AMI. During the study period September 1988 -November 1989, 174 patients with AMI (22% cardiac admissions) were admitted. Forty-three patients received thrombolytic therapy (25%) of which 36 received streptokinase and 7 received alteplase ( Figure 3) . No patient received anistreplase. This was despite the availability of alteplase in 1988 and both alteplase and anistreplase from June 1989. If alteplase had been used in all cases where streptokinase was given the expenditure on alteplase would have exceeded £30,000 based on hospital discounted prices (which were considerably lower than the original £1000 price quoted). The estimated saving resulting from the use of streptokinase instead of alteplase was over £27,000 for the 15-month period. In November and December 1988 and January 1989 there was a small amount of short-dated alteplase available and pharmacy advised that it could be used if requested. Obviously the drug costs in relation to total in-patient costs would need to be considered as part of a thorough cost-benefit analysis investigation; however this information was not available in this study.
Discussion and conclusions
These results show that our policy of recommending streptokinase as first-choice thrombolytic therapy for the management of AMI was supported by the clinicians during this study period. Alteplase was used very rarely. In two patients it was used according to the recommended policy and in five patients it was administered to utilize stock of short-dated alteplase. Anistreplase was not prescribed. In a future study we would plan to identify cases where patients received streptokinase in whom anistreplase would have been more appropriate. We were surprised that streptokinase was not used more often. The use of thrombolytic therapy in AMI has been generally observed to be less than 30% in some studies in acute hospitals.7 This might indicate a need for further reinforcement of our policy.
This study has demonstrated that prescribing of thrombolytic drugs and management of AMI can be influenced by a programme of education by peers and reinforcement by clinicians and pharmacists. It was not the intention of the study to assess total cost-benefit analysis, but to simply measure implementation and voluntary compliance of a policy agreed by local specialists. Full clinical audit would include assessment of patient outcome which was beyond the scope of our current policy. It is important to emphasize that the policy was advisory and clinicians had every opportunity to use the second-line drugs alteplase or anistreplase if they preferred.
Attempts to alter prescribing behaviour should embrace the full cycle of audit.8 The high voluntary compliance with the recommended policy suggests that strong and convincing arguments were proposed in the local policy which encouraged clin- Bulletins provide the ideal opportunity for active ward pharmacy intervention and reinforcement of policies but they need to be reinforced by other change influences.'2 Consultations by pharmacists at ward level, especially with inexperienced clinicians, provide a unique opportunity to strengthen confidence, develop skills and produce long-term attitudinal change in clinicians. '3 In the case of thrombolytic therapy where drugs are administered within 6 hours of onset of symptoms, there is unlikely to be an opportunity for ward pharmacist intervention prior to administration of the drug.
The timing of promotion of our local policy was crucial. We avoided considerable potential confusion by the prompt release of our policy, at or directly after the market launch of the new thrombolytic drugs. Anticipation of these events was possible because we had developed clinical experience and knowledge of the new drugs during clinical trial investigation.
We would recommend the use of this voluntary model for improving patient management in other therapeutic areas in hospital practice and its extension with appropriate reinforcement to general practice medicine.
